查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球PEG化蛋白質市場
市場調查報告書
商品編碼
1311906

2023-2030年全球PEG化蛋白質市場

Global PEGylated Proteins Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

在預測期內，全球PEG化蛋白質市場預計將以1.8%的可觀年複合成長率成長。癌症、腎臟病和類風濕性關節炎等慢性疾病的發病率不斷上升，催生了對這些疾病治療方案的需求，進而推動了全球PEG化蛋白質市場的成長。根據美國癌症協會2022年的資料，估計2022年美國將新增1,908,030例癌症病例。此外，根據同一資料來源，在所有癌症中，消化系統癌症佔343,040例，乳腺癌預計將佔290,560例新發癌症病例，其次是呼吸系統癌症，2022年將有254,850例新發病例。此外，根據聯合國愛滋病規劃署發布的《2022年全球愛滋病毒和愛滋病統計資料》，2021年全球有3840萬人感染愛滋病毒。因此，隨著全球癌症、愛滋病、肺結核等慢性病和傳染病的負擔日益加重，對開發藥物的需求預計也將增加，這將促進蛋白質的研究，推動PEG化蛋白質市場的發展。

生物技術和製藥公司在PEG化蛋白質治療領域的持續研發推動了全球PEG化蛋白質市場的發展。例如，2022年11月，Nektar Therapeutics 在2022年癌症免疫療法協會（SITC）年會上公佈了NKTR-288 的首個臨床前資料。 NKTR-288 是一種新型聚乙二醇（PEG） - γ 干擾素（IFN-γ）共軛物，目的是改變IFN-γ 與其底物的結合，最佳化IFN-γ 訊號傳導的持續時間。 IFN-γ 是一種細胞因子，可誘導細胞抗原呈遞，增強腫瘤抗原特異性細胞毒性T 細胞反應，可應用於多個治療領域，包括腫瘤學和傳染病。

目 錄

第1章：報告摘要

  • 行業現狀分析與成長潛力展望
  • 研究方法和工具
  • 市場細分
    • 按細分市場
    • 按地區

第2章：市場概述與洞察

  • 報告範圍
  • 分析師洞察與當前市場趨勢
    • 主要結論
    • 建議
    • 結論

第3章：競爭格局

  • 主要公司分析
  • Abcam Plc
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • Laysan Bio, Inc.
    • 公司概況
    • 財務分析
    • SWOT 分析
    • 近期發展
  • Thermo Fisher Scientific Inc.
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • 關鍵戰略分析

第4章：市場細分

  • 按產品/服務分類的全球PEG化蛋白質市場
    • 耗材
    • 服務
  • 按最終用戶分類的全球PEG化蛋白質市場
    • 製藥和生物技術公司
    • 契約研究組織
    • 學術研究機構
  • 按應用分類的全球PEG化蛋白質市場
    • 癌症
    • 自身免疫性疾病
    • 肝炎
    • 多發性硬化症
    • 血友病
    • 胃腸道疾病
    • 其他疾病

第5章：地區分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第6章：公司簡介

  • Abcam plc
  • Aurigene Pharmaceutical Services Ltd.
  • Celares GmbH
  • Creative PEGworks
  • Enzon Pharmaceuticals, Inc.
  • Laysan Bio, Inc.
  • Merck KGaA
  • NOF America Corp.
  • Profacgen
  • Thermo Fisher Scientific, Inc.
Product Code: OMR2027513

Title: Global PEGylated Proteins Market Size, Share & Trends Analysis Report Market by Products/ Services (Consumables and Services), by End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic & Research Institutes), and by Application (Cancer, Autoimmune Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders, and Others) Forecast Period (2023-2030).

The global PEGylated proteins market is anticipated to grow at a considerable CAGR of 1.8% during the forecast period. The increasing prevalence of chronic disorders such as cancer, kidney diseases, and rheumatoid arthritis has created demand for their treatment options; which in turn driving the growth of the global PEGylated proteins market. According to the data from the American Cancer Society 2022, an estimated 1,908,030 new cancer cases were diagnosed in the US in 2022. Moreover, as per the same source, among all cancers, digestive system cancer accounts for 343,040 cases, breast cancer is expected to account for 290,560 new cancer cases, followed by respiratory system cancer, with 254,850 new cases in 2022. Additionally, as per the Global HIV and AIDS Statistics, 2022 fact sheet by UNAIDS, 38.4 million people globally were living with HIV in 2021. Thus, with the growing burden of chronic and infectious diseases such as cancer, HIV, tuberculosis, and others globally, the demand for developing medicine is also expected to increase, this will promote the research on protein, thus driving the PEGylated protein market.

The on-going R&D in the field of PEGylated proteins therapeutics by biotechnology and pharmaceutical companies' has driven the global PEGylated proteins market. For instance, in November 2022, Nektar Therapeutics presented 1st preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting. NKTR-288 is a novel polyethylene glycol (PEG)-the conjugate of interferon-gamma (IFN-γ); it is designed to modify the binding of IFN-γ to its substrates and optimize the duration of IFN-γ signaling. IFN-γ is a cytokine that induces cellular antigen presentation and enhances tumor antigen-specific cytotoxic T-cell response and may have applications in several therapeutic areas, including oncology and infectious diseases.

Further in March 2022, Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, announced a EUR 5 million (USD 5.58 million) investment into its protein production and biophysical characterization capabilities and services from its parent company, CRO FairJourneyBiologics S.A. In addition, there is rising adoption of protein-based drugs over non-protein-based drugs wherein PEGylation increases the circulation and half-life of the proteins, improving the efficacy. However, the high drug failure rates and drug recalls are the major factors that may restrain the growth of the global PEGylated proteins market.

Segmental Outlook

The global PEGylated proteins market is segmented based on product/ services, end-user, and application. Based on product/services, the market is bifurcated into consumables and services. Based on end-user, the market is sub-segmented into pharmaceutical & biotechnology companies, contract research organizations, and academic & research institutes. Based on application, the market is sub-segmented into cancer, autoimmune diseases, hepatitis, multiple sclerosis, hemophilia, gastrointestinal disorders, other.

Consumables Sub-Segment to Hold a Considerable Share of the Global PEGylated Proteins Market

Among the product/ services, the consumables sub-segment is expected to hold a considerable share of the market. The consumables sub-segment is further bifurcated into PEGlyation reagents and PEGylation kits. The never-ending research activities, product developments, and the need to formulate better drugs as well as drug-delivery mechanisms contribute to continuous consumption of PEGylating consumables, such as kits and reagents, and thus result in high revenue generation. Moreover, the presence of major players with numerous product offerings also drives segment growth.

The advantages and developments in PEGylation technology along with the increasing demand for PEGylated products have caused a huge adoption of consumables. The versatile application of PEG in research and drug development programs has bolstered its usage. Furthermore, various custom PEG conjugation services & product-providing companies are continuously employing consumables for delivering the intended products. The fast depletion of consumables due to an upswing in demand for PEGylated proteins along with the presence of multiple product providers will contribute to revenue generation in the years to come.

Regional outlooks

The global PEGylated proteins market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Among these, the Asia-Pacific region is anticipated to exhibit a healthy growth during forecast period.

North America to Hold a Major Share in the Global PEGylated Proteins Market

The presence of key players and availability of well established healthcare infrastructure are some of the key factors contributing to the high share of the regional market. According to the estimates of the American Cancer Society, in 2022, it was expected that 79,000 new instances of kidney cancer are likely to be diagnosed in the US in 2022, including 50,290 cases in males and 28,710 cases in women. The top 10 malignancies for both men and women include kidney cancer. Men have about a 1 in 46-lifetime risk of having kidney cancer (2.02%). For women, the lifetime risk is approximately 1 in 80. (1.03%). Thus, the growing prevalence of chronic diseases in the region is likely to propel the growth of the market.

Furthermore, the cohesive government initiatives and an increase in the number of research partnerships are some of the factors anticipated to drive market growth. For instance, in February 2021, Nautilus merged with Arya III, a special purpose acquisition company (SPAC), with an initial investment of $350 million to ramp up work developing its protein analysis technology for drug discovery and diagnostic applications.

Market Players Outlook

The major companies serving the global PEGylated proteins market include: Thermo Fisher Scientific, Inc., Abcam plc, Enzon Pharmaceuticals, Inc., Merck KGaA, and Celares GmbH among others. The market players are considerably contributing to the market growth by the adoption of various strategies, including collaborations, and new product launches, to stay competitive in the market. For instance, In July 2022, The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a favorable opinion, recommending the approval of doxorubicin hydrochloride (Celdoxome pegylated liposomal) for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma, and AIDS-related Kaposi's sarcoma.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global PEGylated proteins market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abcam Plc
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Laysan Bio, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Thermo Fisher Scientific Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global PEGylated Proteins Market by Products/Services
    • 4.1.1. Consumables
    • 4.1.2. Services
  • 4.2. Global PEGylated Proteins Market by End-User
    • 4.2.1. Pharmaceutical & Biotechnology Companies
    • 4.2.2. Contract Research Organizations
    • 4.2.3. Academic & Research Institutes
  • 4.3. Global PEGylated Proteins Market by Application
    • 4.3.1. Cancer
    • 4.3.2. Autoimmune Diseases
    • 4.3.3. Hepatitis
    • 4.3.4. Multiple Sclerosis
    • 4.3.5. Hemophilia
    • 4.3.6. Gastrointestinal Disorders
    • 4.3.7. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abcam plc
  • 6.2. Aurigene Pharmaceutical Services Ltd.
  • 6.3. Celares GmbH
  • 6.4. Creative PEGworks
  • 6.5. Enzon Pharmaceuticals, Inc.
  • 6.6. Laysan Bio, Inc.
  • 6.7. Merck KGaA
  • 6.8. NOF America Corp.
  • 6.9. Profacgen
  • 6.10. Thermo Fisher Scientific, Inc.

LIST OF TABLES

  • 1. GLOBAL PEGYLATED PROTEINS MARKET BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 2. GLOBAL PEGYLATED PROTEINS CONSUMABLES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL PEGYLATED PROTEINS SERVICES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PEGYLATED PROTEINS MARKET BY END-USER, 2022-2030 ($ MILLION)
  • 5. GLOBAL PEGYLATED PROTEINS FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL PEGYLATED PROTEINS FOR CONTRACT RESEARCH ORGANIZATIONS MARKET BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL PEGYLATED PROTEINS FOR ACADEMIC & RESEARCH INSTITUTES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL PEGYLATED PROTEINS MARKET BY APPLICATION, 2022-2030 ($ MILLION)
  • 9. GLOBAL PEGYLATED PROTEINS FOR CANCER TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 10. GLOBAL PEGYLATED PROTEINS FOR AUTOIMMUNE DISEASES TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 11. GLOBAL PEGYLATED PROTEINS FOR HEPATITIS TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 12. GLOBAL PEGYLATED PROTEINS FOR MULTIPLE SCLEROSIS TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 13. GLOBAL PEGYLATED PROTEINS FOR HEMOPHILIA TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 14. GLOBAL PEGYLATED PROTEINS FOR GASTROINTESTINAL DISORDERS TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 15. GLOBAL PEGYLATED PROTEINS FOR OTHER DISEASE TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 16. GLOBAL PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 22. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 23. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 24. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 28. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY PRODUCTS/SERVICES, 2022 VS 2030 (%)
  • 2. GLOBAL PEGYLATED PROTEINS CONSUMABLES MARKET BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL PEGYLATED PROTEINS SERVICES MARKET BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY END-USER, 2022 VS 2030 (%)
  • 5. GLOBAL PEGYLATED PROTEINS FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL PEGYLATED PROTEINS FOR CONTRACT RESEARCH ORGANIZATIONS MARKET BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL PEGYLATED PROTEINS BASED ACADEMIC & RESEARCH INSTITUTES MARKET BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
  • 9. GLOBAL PEGYLATED PROTEINS FOR CANCER MARKET BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL PEGYLATED PROTEINS FOR AUTOIMMUNE DISEASES MARKET BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL PEGYLATED PROTEINS FOR HEPATITIS MARKET BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL PEGYLATED PROTEINS FOR MULTIPLE SCLEROSIS MARKET BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL PEGYLATED PROTEINS FOR HEMOPHILIA MARKET BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL PEGYLATED PROTEINS FOR GASTROINTESTINAL DISORDERS MARKET BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL PEGYLATED PROTEINS FOR OTHER MARKET BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. US PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. CANADA MARKET PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. UK PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SPAIN PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. FRANCE PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. REST OF EUROPE PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. INDIA PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. CHINA PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. JAPAN PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OFASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF WORLD PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)